337 Recruiting Trials

Clinical Trials
for Cancer in Oregon

337 clinical trials for Cancer are currently recruiting participants at study sites in Oregon. Study-related care is provided at no cost.

337
Recruiting trials
224
Study sites
28
Cities
207
Industry-sponsored
130
Phase 2
141
Phase 3

Cancer clinical trials in Oregon: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Oregon, recruiting cancer studies are concentrated in Portland, Eugene, Newberg and Oregon City, with sites in 24 other cities. 207 of the 337 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 337 recruiting Cancer trials in Oregon

Connect for Cancer Prevention Study (Connect)
N/A Denver, Colorado +4 sites NCT04609072
This trial is looking for adults between 30 and 70 years old who have never had cancer. Participants will help researchers learn about cancer risk by answering online health surveys and donating blood, urine, and saliva samples.
Recruiting
IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer
N/A Portland, Oregon +1 sites NCT06206941
This trial is looking for adults with cancer who are receiving immunotherapy treatment. Participants will complete surveys about their symptoms and how they manage them, including the use of cannabis.
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
PHASE3 Goodyear, Arizona +4 sites NCT07213674
This trial is looking for men with specific advanced prostate cancer who have not received chemotherapy. Participants will receive a combination of two medications to see how well they work compared to other treatment options.
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT05827081
This trial is looking for adults with early breast cancer that is hormone receptor positive and HER2 negative. If you join, you will receive ribociclib along with standard hormone therapy to see how effective this combination is.
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites NCT06058377
This trial is looking for women with hormone receptor positive, HER2 negative stage II-III breast cancer. Participants will receive standard chemotherapy along with an immunotherapy drug called durvalumab to see if it helps prevent cancer from coming back.
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
PHASE3 Goodyear, Arizona +4 sites NCT07525206
This trial is looking for adults with hard-to-treat metastatic colorectal cancer. Participants will receive either a new treatment involving telisotuzumab adizutecan combined with bevacizumab or the current standard treatment and will have regular medical check-ups during the study.
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
PHASE3 Dothan, Alabama +4 sites NCT07611110
This trial is looking for men with advanced prostate cancer that hasn't responded to standard treatments. Participants will receive AZD2265 to see if it works better than standard care.
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
PHASE3 Birmingham, Alabama +4 sites NCT07492641
This trial is looking for people with advanced breast cancer who have not been treated for it before. Participants will receive either BGB-43395 with letrozole or a different treatment option with letrozole.
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
PHASE3 Huntsville, Alabama +4 sites NCT07562152
This trial is looking for adults with advanced pancreatic cancer. Participants will receive a combination treatment to see how effective and safe it is compared to standard treatment.
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
PHASE3 Phoenix, Arizona +4 sites NCT06170788
This trial is looking for adults with non-small cell lung cancer that is advanced and has specific characteristics. Participants will receive a combination of sacituzumab tirumotecan and pembrolizumab or pembrolizumab alone to see which treatment helps them live longer.
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
PHASE3 Little Rock, Arkansas +4 sites NCT06312137
This trial is looking for adults with a type of lung cancer called non-small cell lung cancer who did not have a complete response after surgery. Participants will receive medications to see if adding sacituzumab to pembrolizumab helps them stay cancer-free longer.
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
PHASE3 Newport Beach, California +4 sites NCT06452277
This trial is looking for people with advanced non-small cell lung cancer and a specific genetic change called HER2 mutation. Participants will take either the new treatment, sevabertinib, or a standard treatment given by infusion.
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
PHASE3 Phoenix, Arizona +4 sites NCT06925737
This trial is looking for men with advanced prostate cancer that has spread. By participating, I may receive a treatment called ifinatamab deruxtecan and help researchers learn if it works better than standard chemotherapy.
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
PHASE3 Fresno, California +4 sites NCT07195695
This trial is looking for adults who have had surgery for lung cancer and have specific genetic mutations. Participants will take either the new treatment zongertinib or standard care to see which is more effective at preventing cancer from returning.
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
PHASE3 Anchorage, Alaska +4 sites NCT07214779
This trial is looking for women with a specific type of ovarian cancer that hasn't responded to platinum-based treatments. Participants will receive the drug INCB123667 or a chemotherapy chosen by their doctor.
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
PHASE3 Phoenix, Arizona +4 sites NCT06952803
This trial is looking for men with high-risk prostate cancer who have a specific gene mutation. Participants will receive either the drug Saruparib or a placebo along with standard radiation and hormone therapy to see how well they can avoid cancer spread.
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
PHASE2 Goodyear, Arizona +4 sites NCT04613596
This trial is looking for patients with advanced non-small cell lung cancer who have a specific mutation. Participants will receive treatments to see how well they work.
Recruiting

Where the Cancer studies are in Oregon

  • Providence Portland Medical Center, Portland80 trials
  • Oregon Health and Science University, Portland59 trials
  • Providence Saint Vincent Medical Center, Portland59 trials
  • Providence Newberg Medical Center, Newberg49 trials
  • Providence Willamette Falls Medical Center, Oregon City48 trials
  • Saint Alphonsus Cancer Care Center-Ontario, Ontario38 trials

Counts are recruiting studies listing at least one site in Oregon, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Oregon: common questions

How many Cancer clinical trials are recruiting in Oregon?
TrialFinder currently lists 337 recruiting Cancer clinical trials with study sites in Oregon. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Oregon?
Study sites for the Cancer trials listed on this page include Portland. Each trial page lists every participating site with contact details, so you can find the location closest to you.
Do I need insurance to join a Cancer clinical trial in Oregon?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Oregon also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Oregon?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Oregon.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →